Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatment

Samankaltaisia teoksia

• Heightened circulating levels of antimicrobial peptides in tuberculosis—Diabetes co-morbidity and reversal upon treatment
  Tekijä: Kumar, Nathella Pavan, et al.
  Julkaistu: (2017)
• Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors
  Tekijä: Kumar, Nathella Pavan, et al.
  Julkaistu: (2016)
• Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis – Diabetes co-morbidity
  Tekijä: Kumar, Nathella Pavan, et al.
  Julkaistu: (2021)
• Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment
  Tekijä: Kumar, Nathella P., et al.
  Julkaistu: (2018)
• Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden
  Tekijä: Pavan Kumar, Nathella, et al.
  Julkaistu: (2019)